Fluoroquinolones in the treatment of typhoid fever and the carrier state

Abstract

Typhoid fever remains an important public health problem throughout the world with a higher morbidity and mortality rate in the developing countries. Early establishment of the diagnosis and prompt initiation of treatment with chloramphenicol, ampicillin or trimethoprim-sulfamethoxazole is not necessarily followed by complete resolution of the infection. Between 1 % and 6 % of patients with typhoid fever become chronic biliary carriers ofSalmonella typhi. These carriers are potential factors in the continued transmission of the disease. The increasing emergence worldwide of strains showing multiple resistance to the agents traditionally used in therapy has encouraged investigators to seek alternatives such as third generation cephalosporins and recently the new 4-quinolones, which have greater activity againstSalmonella typhi including multi-resistant strains. The fluoroquinolones seem to be the treatment of choice in those regions where resistant strains ofSalmonella typhi are prevalent.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Willis T Practice of physick. Quoted in chapter 2: History of typhoid fever. In: Huckstep RL (ed): Typhoid fever and other salmonella infections. Livingstone, Edinburgh, 1962.

    Google Scholar 

  2. 2.

    Rice PA, Baine WB, Gangarosa EJ Salmonella typhi infections in the United States 1967–1972: increasing importance of international travelers. American Journal of Epidemiology 1977, 106: 160–166.

    PubMed  Google Scholar 

  3. 3.

    Edelman R, Levine MM Summary of an international workshop on typhoid fever. Reviews of Infectious Diseases 1986, 8: 329–349.

    PubMed  Google Scholar 

  4. 4.

    Ashcroft MT The morbidity and mortality of enteric fever in British Guyana. Western Medical Journal 1962, 11: 62–71.

    Google Scholar 

  5. 5.

    Ferrecio C, Levine MM, Manterola A, Rodriguez G, Rivera I, Prenzel I, Black RE, Mancuso T, Bulas D Benign bacteremia caused bySalmonella typhi andparatyphi in children younger than two years. Journal of Pediatrics 1984, 104: 899–901.

    PubMed  Google Scholar 

  6. 6.

    Ryder RW, Blake PA Typhoid fever in the United States, 1975–1976. Journal of Infectious Diseases 1979, 139: 124–126.

    PubMed  Google Scholar 

  7. 7.

    Taylor DN, Pollard RA, Blake PA Typhoid in the United States and the risk to the international traveler. Journal of Infectious Diseases 1983, 148: 599–602.

    PubMed  Google Scholar 

  8. 8.

    Caroline AR, Nancy TH, Paul AB Salmonella typhi infection in the United States, 1975–1984: increasing role of foreign travel. Reviews of Infectious Diseases 1989, 11: 1–8.

    PubMed  Google Scholar 

  9. 9.

    Blaser MJ, Hickman FW, Farmer JJ, Brenner DJ, Balows A, Feldman RA Salmonella typhi, the laboratory as a reservoir of infection. Journal of Infectious Diseases 1980, 142: 934–938.

    PubMed  Google Scholar 

  10. 10.

    Schwalbe RS, Hoge CW, Morris JG, O'Hanlon PN, Crawford RA, Gilligan PH In vivo selection for transmissible drug resistance inSalmonella typhi during antimicrobial therapy. Antimicrobial Agents and Chemotherapy 1990, 34: 161–163.

    PubMed  Google Scholar 

  11. 11.

    Cohen ML, Tauxe RV Drug resistant salmonella in the United States: an epidemiological perspective. Science 1986, 234: 964–969.

    PubMed  Google Scholar 

  12. 12.

    Herzog CH, Geddes AM Chloramphenicol in the treatment of enteric fever. Transactions of the Royal Society of Tropical Medicine and Hygiene 1982, 76: 848–849.

    Article  PubMed  Google Scholar 

  13. 13.

    Snyder MJ, Perroni J, Gonzalez O, Woodward WE, Palomino C, Gonzales C, Music SI, DuPont HL, Hornick RB, Woodward TE Comparative efficacy of chloramphenicol, ampicillin and cotrimoxazole in the treatment of typhoid fever. Lancet 1976, ii: 1155–1157.

    Article  Google Scholar 

  14. 14.

    Hornick RB Typhoid fever. In: Hoeprich PF (ed): Infectious diseases. Harper and Row, Philadelphia 1983, p. 662–668.

    Google Scholar 

  15. 15.

    Finkelstein R, Marcel A, Putterman C, Lerman A, Hashman N, Merabach D Waterborne typhoid fever in Haifa, Israel: clinical, microbiologic and therapeutic aspects of a major outbreak. American Journal of the Medical Sciences 1988, 296: 27–32.

    PubMed  Google Scholar 

  16. 16.

    Hoffman SL, Punjabi NH, Kumala S, Moechar A, Pulungsih SP, Rivai AE, Rockill RC, Woodward TE, Loedin AA Reduction of mortality in chloramphenicol treated severe typhoid fever with high-dose dexamethasone. New England Journal of Medicine 1984, 310: 82–88.

    PubMed  Google Scholar 

  17. 17.

    Abrahan G, Teklu B Typhoid fever: clinical analysis of 50 Ethiopian patients. Ethiopian Medical Journal 1981, 19: 41–46.

    PubMed  Google Scholar 

  18. 18.

    Jean WP, Hans G, Louisa O, Warren DJ Typhoid fever: successful therapy with cefoperazone. Journal of Infectious Diseases 1986, 153: 272–276.

    PubMed  Google Scholar 

  19. 19.

    Agarwal KC, Panhotra BR, Mahanta J, Arya VK, Garg RK Typhoid fever due to chloramphenicol resistantSalmonella typhi associated with R-plasmid. Indian Journal of Medical Research 1981, 73: 384–388.

    Google Scholar 

  20. 20.

    Olarte J, Galindo E Salmonella typhi resistant to chloramphenicol, ampicillin and other antimicrobial agents. Antimicrobial Agents and Chemotherapy 1973, 4: 597–601.

    PubMed  Google Scholar 

  21. 21.

    Colquhoun J, Weetch RS Resistance to chloramphenicol developing during treatment of typhoid fever. Lancet 1950, ii: 621–623.

    Article  Google Scholar 

  22. 22.

    Ward LR, Rowe B, Threlfall EJ Incidence of trimethoprim resistance in salmonella isolated in Britain: a twelve year study. Lancet 1982, ii: 705–706.

    Article  Google Scholar 

  23. 23.

    Datta N, Richards H, Datta C Salmonella typhi in vivo acquires resistance to both chloramphenicol and cotrimoxazole. Lancet 1981, i: 1181–1183.

    Article  Google Scholar 

  24. 24.

    Butler T, Link N, Arnold K, Pollack M Chloramphenicol resistant typhoid fever in Vietnam associated with R-factor. Lancet 1973, ii: 983–985.

    Google Scholar 

  25. 25.

    Gonzalez-Cortes AD, Bessuda R, Sanchez-Leyva N, Fragosa R, Hinojosa M, Becerril P Waterborne transmission of chloramphenicol resistantSalmonella typhi in México. Lancet 1973, i: 605–607.

    Article  Google Scholar 

  26. 26.

    Lampe RM, Mansuwan P, Duagmanii C Chloramphenicol resistant typhoid. Lancet 1974, i: 623–624.

    Article  Google Scholar 

  27. 27.

    Cohen SL, Wylic BA, Sooka A, Koornhof HJ Bacteremia caused by a lactose fermenting, multiple resistantSalmonella typhi strain in a patient recovering from typhoid fever. Journal of Clinical Microbiology 1987, 25: 1516–1518.

    PubMed  Google Scholar 

  28. 28.

    Goldstein FW, Chumpitaz JC, Guevara JM, Papadopoulou B, Acar JF, Viev JF Plasmid-mediated resistance to multiple antibiotics inSalmonella typhi. Journal of Infectious Diseases 1986, 153: 261–265.

    PubMed  Google Scholar 

  29. 29.

    Kohbata SM, Takahahashi N, Yabunchi E Lactose fermenting multiple drug-resistantSalmonella typhi strains isolated from patients with postoperative typhoid fever. Journal of Clinical Microbiology 1983, 18: 920–925.

    PubMed  Google Scholar 

  30. 30.

    Hoffman TA, Ruiz CJ, Counts CW Waterborne typhoid fever in Dade County, Florida: clinical and therapeutic evaluation of 105 bacteremic patients. American Journal of Medicine 1975, 59: 481–487.

    Article  PubMed  Google Scholar 

  31. 31.

    Guerra-Caceres JG, Gotuzzo-Herencia E, Crosby-Dagnino E, Micro-Quesada M, Carrillo-Parodi C Diagnostic value of bone marrow culture in typhoid fever. Transactions of the Royal Society of Tropical Medicine and Hygiene 1970, 73: 680–683.

    Article  Google Scholar 

  32. 32.

    Kaye D, Rocha H, Eyckmans L, Prata A, Hoot EW Comparison of parenteral ampicillin and parenteral chloramphenicol in the treatment of typhoid fever. Annals of the New York Academy of Sciences 1967, 145: 423–428.

    PubMed  Google Scholar 

  33. 33.

    Robertson RP, Wahab MFA, Raasch FO Evaluation of chloramphenicol and ampicillin in salmonella enteric fever. New England Journal of Medicine 1986, 278: 171–176.

    Google Scholar 

  34. 34.

    Kamat SA Evaluation of therapeutic efficacy of trimethoprim sulfamethoxazole and chloramphenicol in enteric fever. British Medical Journal 1970, iii: 3320–3322.

    Google Scholar 

  35. 35.

    Scragg IN, Rubidge CJ Trimethoprim and sulfamethoxazole in typhoid fever in children. British Medical Journal 1971, iii: 738–741.

    Google Scholar 

  36. 36.

    Hamilton-Miller JMT, Brumfitt W, Reynolds AV Cefotaxime (HR-756), a new cephalosporin with exceptional broad-spectrum activity in vitro. Journal of Antimicrobial Chemotherapy 1978, 4: 437–444.

    PubMed  Google Scholar 

  37. 37.

    Shah PM, Troche G, Stile W In vitro activity of HR 756, a new cephalosporin compound. Journal of Antibiotics (Tokyo) 1978, 31: 1170–1174.

    PubMed  Google Scholar 

  38. 38.

    Chau PY, Ng WS, Ling J, Arnold K In vitro susceptibility of salmonella to various antimicrobial agents, including a new cephalosporin, Ro 13-9904. Antimicrobial Agents and Chemotherapy 1981, 19: 8–11.

    PubMed  Google Scholar 

  39. 39.

    Cleeland R, Squires E Antimicrobial activity of ceftriaxone: a review. American Journal of Medicine 1984, 77, Supplement 4C: 3–11.

    Article  Google Scholar 

  40. 40.

    Aukenthaler R, Waldvogel FA In vitro activity of a new semisynthetic cephalosporin, cefoperazone. Clinical Therapeutics 1980, 3, Special Issue: 89–97.

    PubMed  Google Scholar 

  41. 41.

    Olarte J In vitro activity of cefoperazone against clinical isolates ofEnterobacteriaceae, Pseudomonas andStaphylococcus. Clinical Therapeutics 1980, 3, Special Issue: 130–133.

    PubMed  Google Scholar 

  42. 42.

    Butler T, Linh MN, Arnold K, Adichman MD, Chau DM, Muoi MM Therapy of antimicrobial resistant typhoid fever. Antimicrobial Agents and Chemotherapy 1977, 11: 645–650.

    PubMed  Google Scholar 

  43. 43.

    Cherubin CE, Eng RHK, Smith SM, Goldstein EJC Cephalosporin therapy for salmonellosis: question of efficacy and cross-resistance with ampicillin. Archives of Internal Medicine 1986, 146: 2149–2152.

    Article  PubMed  Google Scholar 

  44. 44.

    Garwin B, Soe G, Overturf D Treatment of typhoid fever and other systemic salmonellosis with cefotaxime, ceftriaxone, cefoperazone and other newer cephalosporins. Reviews of Infectious Diseases 1987, 4: 719–736.

    Google Scholar 

  45. 45.

    Tulio M, Anna MM, Maria GD, Gavino F, Lino A Ceftriaxone treatment of salmonella enteric fever. Pediatric Infectious Diseases 1988, 10: 734–735.

    Google Scholar 

  46. 46.

    Eykyn SJ, Williams H Treatment of multiresistantSalmonella typhi with oral ciprofloxacin. Lancet 1987, ii: 1407–1408.

    Article  Google Scholar 

  47. 47.

    Jean-Jaques P Use of fluoroquinolones for intracellular pathogens. Reviews of Infectious Diseases 1989, 11, Supplement 5: 979–984.

    Google Scholar 

  48. 48.

    Adhami ZN, Wise R, Weston D, Crump B The pharmacokinetics and tissue penetration of norfloxacin. Journal of Antimicrobial Chemotherapy 1984, 13: 87–92.

    PubMed  Google Scholar 

  49. 49.

    Lockley MR, Wise R, Dent J The pharmacokinetics and tissue penetration of ofloxacin. Journal of Antimicrobial Chemotherapy 1984, 14: 647–652.

    PubMed  Google Scholar 

  50. 50.

    Velmonte MA, Montalban CS Norfloxacin in treatment of infections caused bySalmonella typhi. Scandinavian Journal of Infectious Diseases 1988, Supplement 56: 46–48.

    PubMed  Google Scholar 

  51. 51.

    Gotuzzo E, Benavente L, Gerra J, Maguina C, Carrillo C: Relapse in typhoid fever. International Congress of Infectious Diseases, Rio de Janeiro, 1988, Abstract no. 496.

  52. 52.

    Cristiano P, Morelli G: Therapeutic role of fluoroquinolones in the therapy of typhoid fever. Western Pacific Congress on Infectious Diseases and Chemotherapy, Kuala Lumpur, 1989, Abstract OR 9/6.

  53. 53.

    Nalim DR, Hoagland VL, Acuña G, Bran JL, Carrillo C, Gotuzzo E, Ruiz Palacios G, Ramirez C, Guerra J: Clinical trial of norfloxacin versus chloramphenicol therapy for acute typhoid fever. Proceedings of the 15th International Congress of Chemotherapy, Istanbul, 1987, p. 1174.

  54. 54.

    Gotuzzo E, Guerra JG, Benavente L, Palomino JC, Carrillo C, Lopera J, Delgado F, Nalim DR, Sabbaj J Use of norfloxacin to treat chronic typhoid carrier. Journal of Infectious Diseases 1988, 157: 1221–1225.

    PubMed  Google Scholar 

  55. 55.

    Ramirez CA, Bran JL, Mejia CR, Garcia JF Open prospective study of the clinical efficacy of ciprofloxacin. Antimicrobial Agents and Chemotherapy 1985, 28: 128–132.

    PubMed  Google Scholar 

  56. 56.

    Limson BM Efficacy and safety of ciprofloxacin in uncomplicated typhoid fever. In: Neu HC, Weuta H (ed): First International Ciprofloxacin Workshop. Excerpta Medica, Amsterdam, 1986, p. 362.

    Google Scholar 

  57. 57.

    Peyramond E, Tigaud S, Lucht F, Vedrine JM, Salford F, Bertrand JL Clinical evaluation of ofloxacin in the treatment of various infections. Pathologie Biologie 1986, 34: 471–475.

    PubMed  Google Scholar 

  58. 58.

    Lo WL Ofloxacin in the treatment of typhoid fever, preliminary study. Journal of Antimicrobial Chemotherapy 1988, 21: 681–682.

    PubMed  Google Scholar 

  59. 59.

    Wang F, Gu XJ, Zhang MF, Tai TY Treatment of typhoid fever with ofloxacin. Journal of Antimicrobial Chemotherapy 1989, 23: 785–788.

    PubMed  Google Scholar 

  60. 60.

    Cristiano P, Morelli G, Briante V, Iovene MR, Simioli F, Altucci P Clinical experience with pefloxacin in the therapy of typhoid fever. Infection 1989, 17: 86–87.

    Article  PubMed  Google Scholar 

  61. 61.

    Isidro ZT, Arnulfo NZ, Guadalupe M, Martha R Fleroxacin in the treatment of enteric fever and salmonellosis in adults. Reviews of Infectious Diseases 1989, 11, Supplement 5: 1118–1119.

    Google Scholar 

  62. 62.

    Dinbar A, Altmann G, Tuleinsky DB The treatment of chronic biliary salmonella carriers. American Journal of Medicine 1969, 47: 236–242.

    Article  PubMed  Google Scholar 

  63. 63.

    White PC JR, Walls RC, Gresham EA: A review of reported cases of typhoid fever and documented carriers in Arkansas. Journal of the Arkansas Medical Society, 79: 47–49.

  64. 64.

    Phillips WE Treatment of chronic typhoid carriers with ampicillin. Journal of the American Medical Association 1971, 217: 913–915.

    Article  PubMed  Google Scholar 

  65. 65.

    Nolan CM, White PC Treatment of typhoid carriers with amoxicillin: correlates of successful therapy. Journal of the American Medical Association 1978, 239: 2352–2354.

    Article  PubMed  Google Scholar 

  66. 66.

    Farid Z, Bassily S, Milkhail IA, Edman DC, Hassan A, Miner WF Treatment of chronic enteric fever with amoxicillin. Journal of Infectious Diseases 1975, 132: 698–701.

    PubMed  Google Scholar 

  67. 67.

    Brodie J, Macquee IA, Livingstone D Effect of trimethoprim-sulfamethoxazole on typhoid and salmonella carriers. British Medical Journal 1970, iii: 318–319.

    Google Scholar 

  68. 68.

    Munnich D, Bekesi S Curing of typhoid carriers by cholecystectomy combined with amoxicillin plus probenecid treatment. Chemotherapy 1979, 25: 362–366.

    PubMed  Google Scholar 

  69. 69.

    Juhani L Ciprofloxacin in the elimination of enteric salmonella carrier state. Scandinavian Journal of Infectious Diseases 1989, Supplement 60: 1112–1115.

    Google Scholar 

  70. 70.

    DuPont HL, Corrado MK, Sabbaj J The use of norfloxacin in the treatment of acute diarrheal disease. American Journal of Medicine 1987, 82, Supplement 6B: 70–74.

    Article  PubMed  Google Scholar 

  71. 71.

    Asma I, Thomas B, Samir KN, Nurul HA, Klaus S, Harol BH, Arnold IS Randomized treatment of patients with typhoid fever by using ceftriaxone, or chloramphenicol. Journal of Infectious Diseases 1988, 158: 742–747.

    PubMed  Google Scholar 

  72. 72.

    Butler T, Rumans L, Arnold K Response of typhoid fever caused by chloramphenicol-susceptible and chloramphenicol resistant strains ofSalmonella typhi to treatment with trimethoprim-sulfamethoxazole. Reviews of Infectious Diseases 1982, 4: 551–561.

    PubMed  Google Scholar 

  73. 73.

    Gilman RH, Terminel M, Levine MM, Hernandez-Mendoza P, Calderon E, Vasquez V, Martinez E, Snyder MJ, Hornick RB Comparison of trimethoprim-sulfamethoxazole and amoxicillin in therapy of chloramphenicol resistant and chloramphenicol sensitive typhoid fever. Journal of Infectious Diseases 1975, 132: 630–636.

    PubMed  Google Scholar 

  74. 74.

    Jones RN, Thornsberry C Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity. Reviews of Infectious Diseases 1982, Supplement 4: 300–315.

    Google Scholar 

  75. 75.

    Masuyoshi S, Arai S, Miyamoto M, Mitsuhashis N In vitro antimicrobial activity of cefotaxime, a new cephalosporin. Antimicrobial Agents and Chemotherapy 1980, 18: 1–8.

    PubMed  Google Scholar 

  76. 76.

    Clarke AM, Zemcov SJV Ro 13-9904 and Gr 20263, two new cephalosporins with broad-spectrum activity: an in vitro comparison with other β-lactam antibiotics. Journal of Antimicrobial Chemotherapy 1981, 7: 515–520.

    PubMed  Google Scholar 

  77. 77.

    Kamimura T, Matsumoto Y, Okada N, Mine Y, Nishida M, Goto S, Kuwahara S Ceftriaxone (FK 749) a new parenteral cephalosporin: in vitro and in vivo antibacterial activities. Antimicrobial Agents and Chemotherapy 1979, 16: 540–548.

    PubMed  Google Scholar 

  78. 78.

    Barry AL, Thornsberry RN In vitro evaluation of LY 127935 (60595) compared with cefotaxime, eight other β-lactams and two aminoglycosides. Journal of Antimicrobial Chemotherapy 1980, 6: 775–784.

    PubMed  Google Scholar 

  79. 79.

    Keusch GT Antimicrobial therapy for enteric infection and typhoid fever. Reviews of Infectious Diseases 1988, 10, Supplement 1: 199–205.

    Google Scholar 

  80. 80.

    Auckenthaler R, Michea-Hamzehpour M, Pechère JC In vitro activity of newer quinolones against aerobic bacteria. Journal of Antimicrobial Chemotherapy 1986, 17, Supplement B: 29–30.

    PubMed  Google Scholar 

  81. 81.

    Hannan A In vitro activity of ofloxacin against 210 clinical isolates of typhoid salmonellae. Infection 1986, 14, Supplement 4: 243–244.

    Article  PubMed  Google Scholar 

  82. 82.

    Hol P, von Graevenitz A, Zollinger I Effects of fleroxacin in vitro on common bacteria causing diarrhea, includingVibrionaceae. Reviews of Infectious Diseases 1988, 10, Supplement 1: 209–210.

    Google Scholar 

  83. 83.

    Ferrecio C, Morris JG, Valdivieso C, Prenzel I, Sotomayor V, Drusano GL, Levine MM Efficacy of ciprofloxacin in the treatment of chronic carriers. Journal of Infectious Diseases 1988, 157: 1235–1239.

    PubMed  Google Scholar 

  84. 84.

    Reid T, Smith C Ciprofloxacin treatment of chronic salmonella excretors. Chemotherapy 1987, 6, Supplement 2: 485–486.

    Google Scholar 

  85. 85.

    Diridl G, Pichler H, Wolf D Treatment of chronic salmonella carriers with ciprofloxacin. European Journal of Clinical Microbiology 1986, 5: 260–261.

    PubMed  Google Scholar 

  86. 86.

    Hornick RB, Greisman SE, Woodward TE, DuPont HL, Dawfins AT, Synedor MJ Typhoid fever: pathogenesis and immunologic control. New England Journal of Medicine 1970, 283: 686–691.

    PubMed  Google Scholar 

  87. 87.

    Hornick RB Selective primary health care: strategies for control of disease in the developing world. Typhoid fever. Reviews of Infectious Diseases 1985, 7: 536–546.

    PubMed  Google Scholar 

  88. 88.

    Nord CE Effect of new quinolones on the human gastrointestinal microflora. Reviews of Infectious Diseases 1988, 10, Supplement 1: 193–196.

    Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to I. Zavala Trujillo.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Trujillo, I.Z., Quiroz, C., Gutierrez, M.A. et al. Fluoroquinolones in the treatment of typhoid fever and the carrier state. Eur. J. Clin. Microbiol. Infect. Dis. 10, 334–341 (1991). https://doi.org/10.1007/BF01967008

Download citation

Keywords

  • Ampicillin
  • Chloramphenicol
  • Cephalosporin
  • Public Health Problem
  • Fluoroquinolones